… , could be a predictor of response to temozolomide in pituitary tumours.9-11 … of aggressive
pituitary tumours and carcinomas. We will then discuss the potential use of temozolomide in …

… to predict response to temozolomide in pituitary tumours [16,17]. In this paper, we will review
the use of temozolomide in the management of aggressive pituitary tumours and discuss …

… the efficacy of temozolomide treatment for some aggressive pituitary tumors or carcinomas;
however, the study reveals MGMT status as a poor predictor of treatment outcome that should …

… is effective in some patients with progressive pituitary adenoma or carcinoma. We …
Temozolomide because of aggressive pituitary adenoma or carcinoma resistant to standard …

… the efficacy of temozolomide for treating aggressive pituitary adenomas and carcinomas (5-…
we discuss the indications, results and side effects of temozolomide therapy. Temozolomide …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ)
in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

… to temozolomide treatment, whereas that with high levels was resistant to treatment ( 6 ). …
distinct possibility of using temozolomide to treat aggressive pituitary adenomas. However, our …

… , clinically aggressive pituitary tumors are not at all exceptional and pose special therapeutic
… useless and usual drug therapy is of variable and unpredictable efficacy. So called “silent” …

… PCs are extremely rare accounting for only 0.12% of pituitary tumors (8). The use of
temozolomide (TMZ) for the treatment of aggressive pituitary tumors (APTs) and PCs was first …

… , temozolomide, a second generation oral alkylating agent, has shown therapeutic promise
for aggressive pituitary adenomas … Temozolomide causes DNA damage by methylation of the …